94 related articles for article (PubMed ID: 11477560)
1. Humanization and characterization of the anti-HLA-DR antibody 1D10.
Kostelny SA; Link BK; Tso JY; Vasquez M; Jorgensen BH; Wang H; Hall WC; Weiner GJ
Int J Cancer; 2001 Aug; 93(4):556-65. PubMed ID: 11477560
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.
Stein R; Qu Z; Chen S; Solis D; Hansen HJ; Goldenberg DM
Blood; 2006 Oct; 108(8):2736-44. PubMed ID: 16778139
[TBL] [Abstract][Full Text] [Related]
3. Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody.
Stockmeyer B; Schiller M; Repp R; Lorenz HM; Kalden JR; Gramatzki M; Valerius T
Br J Haematol; 2002 Sep; 118(4):959-67. PubMed ID: 12199773
[TBL] [Abstract][Full Text] [Related]
4. In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells.
Shi JD; Bullock C; Hall WC; Wescott V; Wang H; Levitt DJ; Klingbeil CK
Leuk Lymphoma; 2002 Jun; 43(6):1303-12. PubMed ID: 12153000
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma.
Stein R; Balkman C; Chen S; Rassnick K; McEntee M; Page R; Goldenberg DM
Leuk Lymphoma; 2011 Feb; 52(2):273-84. PubMed ID: 21133722
[TBL] [Abstract][Full Text] [Related]
7. Production and characterization of a bispecific IgG capable of inducing T-cell-mediated lysis of malignant B cells.
Link BK; Weiner GJ
Blood; 1993 Jun; 81(12):3343-9. PubMed ID: 8507872
[TBL] [Abstract][Full Text] [Related]
8. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.
Leung SO; Shevitz J; Pellegrini MC; Dion AS; Shih LB; Goldenberg DM; Hansen HJ
Hybridoma; 1994 Dec; 13(6):469-76. PubMed ID: 7737671
[TBL] [Abstract][Full Text] [Related]
9. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells.
Nagy ZA; Hubner B; Löhning C; Rauchenberger R; Reiffert S; Thomassen-Wolf E; Zahn S; Leyer S; Schier EM; Zahradnik A; Brunner C; Lobenwein K; Rattel B; Stanglmaier M; Hallek M; Wing M; Anderson S; Dunn M; Kretzschmar T; Tesar M
Nat Med; 2002 Aug; 8(8):801-7. PubMed ID: 12101408
[TBL] [Abstract][Full Text] [Related]
10. A bispecific antibody directly induces lymphoma cell death by simultaneously targeting CD20 and HLA-DR.
Zeng J; Liu R; Wang J; Fang Y
J Cancer Res Clin Oncol; 2015 Nov; 141(11):1899-907. PubMed ID: 25773122
[TBL] [Abstract][Full Text] [Related]
11. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.
Dechant M; Vidarsson G; Stockmeyer B; Repp R; Glennie MJ; Gramatzki M; van De Winkel JG; Valerius T
Blood; 2002 Dec; 100(13):4574-80. PubMed ID: 12393717
[TBL] [Abstract][Full Text] [Related]
12. Production and characterization of chimeric anti-HLA monoclonal antibodies targeting public epitopes as tools for standardizations of the anti-HLA antibody detection.
Congy-Jolivet N; Drocourt D; Portet S; Tiraby G; Blancher A
J Immunol Methods; 2013 Apr; 390(1-2):41-51. PubMed ID: 23352853
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma.
Wu L; Wang C; Zhang D; Zhang X; Qian W; Zhao L; Wang H; Li B; Guo Y
Cancer Lett; 2010 Jun; 292(2):208-14. PubMed ID: 20056316
[TBL] [Abstract][Full Text] [Related]
14. The monoclonal antibody TAL16.1 recognizes the aspartic acid residue at position 70 in DRB gene products.
Sadler AM; Heyes JM; Marsh SG; Krausa P; Reynolds GE; Bodmer JG
Tissue Antigens; 1993 Jan; 41(1):42-6. PubMed ID: 7681224
[TBL] [Abstract][Full Text] [Related]
15. IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma.
Cardillo TM; Govindan SV; Zalath MB; Rossi DL; Wang Y; Chang CH; Goldenberg DM
Mol Cancer Ther; 2018 Jan; 17(1):150-160. PubMed ID: 29133623
[TBL] [Abstract][Full Text] [Related]
16. Critical Lym-1 binding residues on polymorphic HLA-DR molecules.
Rose LM; Deng CT; Scott SL; Xiong CY; Lamborn KR; Gumerlock PH; DeNardo GL; Meares CF
Mol Immunol; 1999 Aug; 36(11-12):789-97. PubMed ID: 10593517
[No Abstract] [Full Text] [Related]
17. A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4(+) T lymphocytes.
Rajnavölgyi E; Nagy N; Thuresson B; Dosztányi Z; Simon A; Simon I; Karr RW; Ernberg I; Klein E; Falk KI
Int Immunol; 2000 Mar; 12(3):281-93. PubMed ID: 10700463
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody SN10 which shows a highly selective reactivity with human B leukemia-lymphoma and is effectively internalized into cells.
Takeuchi T; Barcos MP; Seon BK
Cancer Res; 1991 Jun; 51(11):2985-93. PubMed ID: 1709587
[TBL] [Abstract][Full Text] [Related]
19. Preparation of human IgG and IgM monoclonal antibodies for MK-1/Ep-CAM by using human immunoglobulin gene-transferred mouse and gene cloning of their variable regions.
Kuroki M; Yamada H; Shibaguchi H; Hachimine K; Hirose Y; Kinugasa T; Ishida I; Kuroki M
Anticancer Res; 2005; 25(6A):3733-9. PubMed ID: 16302733
[TBL] [Abstract][Full Text] [Related]
20. RT-PCR cloning and characterization of mouse immunoglobulin variable domains with high affinity for HLA-DR antigens.
Eswarakumar VP; Raja MC; Muthukkaruppan VR
Immunogenetics; 1997; 46(3):249-50. PubMed ID: 9211753
[No Abstract] [Full Text] [Related]
[Next] [New Search]
